Biotech Values

[DewDiligence]

ESPR—Respectfully disagree with Larry Huston’s contention that a failure of MRK’s IMPROVE-IT study will drastically alter regulators’ acceptance of LDL as a surrogate endpoint. IMPROVE-IT failure will have some ramifications, of course, but it won’t (IMO) preclude the approval of relatively safe small-molecule drugs such as ETC-1002, based primarily on LDL and secondarily on other biomarkers such as CRP.